Suchergebnisse
16. Nov. 2018 · Adrenomed AG. @adrenomed. An innovative biomarker-guided #precisionmedicine solution for patients in acute care with #sepsis and #septicshock. #enibarcimab. Hennigsdorf, Deutschland adrenomed.com Joined November 2018. 218 Following.
13. Okt. 2022 · In #November, meet our CEO and CFO at: @LSXLeaders’ Inv€$tival #Showcase November 14, 2022, in-person in #London, UK
AdrenoMed AG is a privately-financed, clinical-stage biopharmaceutical company with a clear mission: developing precision medicine to rescue vascular integrity and saving the lives of critically ill patients with limited treatment options.
13. Okt. 2022 · Adrenomed appoints Dr. med. Steffen Stürzebecher as Chief Medical Officer Hennigsdorf/Berlin (Germany), June 23, 2022 – Adrenomed AG, the vascular integrity company, today announced the appointment of Dr. med. Steffen Stürzebecher as Chief Medical Officer (CMO) of Adrenomed, effective June 20, 2022. Dr. Stürzebecher is Read More »
2. Dez. 2021 · Adrecizumab has successfully completed a biomarker-guided, double-blinded, placebo-controlled, randomized, multicenter proof-of-concept Phase II trial with 301 patients suffering from septic shock. For further information, please visit www.adrenomed.com and follow us on LinkedIn and Twitter.
Adrenomed AG is a German privately financed, clinical-stage biopharmaceutical company. Adrenomed’s mission is to rescue vascular integrity in order to save the lives of critically ill...
2. Dez. 2021 · Der “first-in-class” Antikörper zielt auf das gefäßschützende Peptid Adrenomedullin ab, um die vaskuläre Integrität bei Patienten mit frühem septischen Schock, einer lebensbedrohlichen Erkrankung mit sehr begrenzten Behandlungsmöglichkeiten, wiederherzustellen.
